{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06110663","nct_id":"NCT06110663","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06110663. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Experimental group (Experimental): HS-10241 combined with Almonertinib NSCLC with MET amplification after failure of EGFR-TKI treatment randomized to HS-10241 combined with Almonertinib","label":"HS-10241+Almonertinib","type":"EXPERIMENTAL"},{"description":"Control group (Active Comparator): Pemetrexed combined with Platinum NSCLC with MET amplification after failure of EGFR-TKI treatment randomized to standard chemotherapy treatment of platinum-based chemotherapy","label":"Pemetrexed + Cisplatin /Carboplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-02-28","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":314,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"HS-10241+ Almonertinib","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed + Cisplatin /Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2023-11-01","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","official_title":"A Phase 3, Randomized, Open-label, Multicenter Study to Assess the Efficacy and Safety of HS-10241 Combined With Almonertinib Versus Pemetrexed Combined With Platinum in Metastatic or Locally Advanced NSCLC With MET Amplification After Failure of the Prior EGFR -TKI Therapy","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)","timeFrame":"From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, assessed up to 24 months"}],"references":[],"start_date":{"date":"2023-12-30","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","url":"https://clinicaltrials.gov/study/NCT06110663"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06110663"}